JP2010509326A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010509326A5 JP2010509326A5 JP2009536219A JP2009536219A JP2010509326A5 JP 2010509326 A5 JP2010509326 A5 JP 2010509326A5 JP 2009536219 A JP2009536219 A JP 2009536219A JP 2009536219 A JP2009536219 A JP 2009536219A JP 2010509326 A5 JP2010509326 A5 JP 2010509326A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- food
- balsalazide
- acid compound
- aminosalicylic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/592,854 US8921344B2 (en) | 2006-11-03 | 2006-11-03 | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
| US11/592,854 | 2006-11-03 | ||
| PCT/US2007/007438 WO2008063211A2 (en) | 2006-11-03 | 2007-03-23 | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012248573A Division JP2013032395A (ja) | 2006-11-03 | 2012-11-12 | ２−ヒドロキシ−５−フェニル安息香酸誘導体の処方および使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010509326A JP2010509326A (ja) | 2010-03-25 |
| JP2010509326A5 true JP2010509326A5 (enExample) | 2011-03-03 |
| JP6067203B2 JP6067203B2 (ja) | 2017-01-25 |
Family
ID=38263983
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009536219A Expired - Fee Related JP6067203B2 (ja) | 2006-11-03 | 2007-03-23 | ２−ヒドロキシ−５−フェニル安息香酸誘導体の処方および使用 |
| JP2012248573A Pending JP2013032395A (ja) | 2006-11-03 | 2012-11-12 | ２−ヒドロキシ−５−フェニル安息香酸誘導体の処方および使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012248573A Pending JP2013032395A (ja) | 2006-11-03 | 2012-11-12 | ２−ヒドロキシ−５−フェニル安息香酸誘導体の処方および使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8921344B2 (enExample) |
| EP (1) | EP2096912B1 (enExample) |
| JP (2) | JP6067203B2 (enExample) |
| KR (2) | KR20140098863A (enExample) |
| CN (1) | CN101610670A (enExample) |
| AU (1) | AU2007322362B2 (enExample) |
| BR (1) | BRPI0717859A2 (enExample) |
| CA (2) | CA3004028C (enExample) |
| DK (1) | DK2096912T3 (enExample) |
| IL (1) | IL198513B (enExample) |
| MX (1) | MX2009004826A (enExample) |
| WO (1) | WO2008063211A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2359812C (en) | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
| JP2007520495A (ja) | 2004-02-06 | 2007-07-26 | ボロディー トーマス ユリウス | 下痢型過敏性腸症候群におけるアミノサリチル酸の使用法 |
| US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
| US8217083B2 (en) * | 2007-06-08 | 2012-07-10 | Aptalis Pharma Canada Inc. | Mesalamine suppository |
| US7541384B2 (en) | 2007-06-08 | 2009-06-02 | Axcan Pharma Inc. | Mesalamine suppository |
| US8436051B2 (en) | 2007-06-08 | 2013-05-07 | Aptalis Pharma Canada Inc. | Mesalamine suppository |
| ITMI20071965A1 (it) * | 2007-10-11 | 2009-04-12 | Domenico Russo | Composizione farmaceutica comprendente sucralfato e mesalazina |
| CA2739465C (en) * | 2008-10-03 | 2017-01-31 | Dr. Falk Pharma Gmbh | Compositions and methods for the treatment of bowel diseases with granulated mesalamine |
| AU2009333303A1 (en) * | 2008-12-17 | 2011-08-11 | Altheus Therapeutics, Inc. | Enema formulations |
| EP2440210A4 (en) | 2009-06-12 | 2014-01-29 | Meritage Pharma Inc | METHOD FOR THE TREATMENT OF STOMACH DARM DISEASES |
| BR122014009845A2 (pt) * | 2010-04-26 | 2015-12-29 | Salix Pharmaceuticals Ltd | usos de balsalazida para preparação de composição farmacêutica para tratamento de distúrbio gastrointestinal e induzir remissão clínica de colite ulcerativa em indivíduos do sexo masculino, bem como para diminuir o escore de mmdai e cicatrização da mucosa em indivíduos do sexo masculino com colite ulcerativa |
| PT3222280T (pt) * | 2010-12-03 | 2021-04-22 | Nalpropion Pharmaceuticals Llc | Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona |
| CN103483220B (zh) * | 2013-06-09 | 2015-06-17 | 陕西新药技术开发中心 | 一种化合物及其制备方法和抗溃疡性结肠炎用途 |
| CN103333084B (zh) * | 2013-06-09 | 2015-01-07 | 陕西新药技术开发中心 | 3,3’-偶氮双[6-(丁酰氧基)苯甲酸]及其制备方法和应用 |
| CN104706582A (zh) * | 2013-12-12 | 2015-06-17 | 四川健能制药有限公司 | 含有美沙拉秦的药物组合物 |
| US10100005B1 (en) * | 2017-11-17 | 2018-10-16 | Eclipse Therapeutics, LLC | Mesalazine derivatives |
| JP2020090456A (ja) * | 2018-12-05 | 2020-06-11 | 日本化薬株式会社 | エルロチニブを有効成分とする医薬錠剤 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE791889A (fr) | 1971-11-26 | 1973-05-24 | Pharmacia Ab | Nouveaux derives de la pyridine |
| US4298595A (en) | 1978-12-20 | 1981-11-03 | Dynapol | Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract |
| US4960765A (en) | 1980-03-20 | 1990-10-02 | Farmaceutisk Laboratorium Ferring A/S | Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration |
| WO1981002671A1 (en) | 1980-03-20 | 1981-10-01 | Ferring Farma Lab | Pharmaceutical composition and method for the treatment of colitis ulcerosa and crohn's disease by oral administration |
| EP0039306B1 (de) | 1980-03-28 | 1984-01-11 | Ciba-Geigy Ag | Neue Azofarbstoffe, Verfahren zu deren Herstellung und deren Verwendung |
| US4412922A (en) | 1980-07-02 | 1983-11-01 | Abcor, Inc. | Positive-charged ultrafiltration membrane for the separation of cathodic/electrodeposition-paint compositions |
| US4412992A (en) | 1980-07-21 | 1983-11-01 | Biorex Laboratories Limited | 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith |
| ZA825384B (en) | 1981-07-31 | 1983-05-25 | Tillott J B Ltd | Orally administrable pharmaceutical compositions |
| US4562024A (en) | 1982-07-06 | 1985-12-31 | Sterling Drug Inc. | Process for preparing granulate containing poorly compressible medicinally active matter |
| SE8405924L (sv) | 1984-11-23 | 1986-05-24 | Pharmacia Ab | Nya azoforeningar |
| US4781925A (en) * | 1986-03-06 | 1988-11-01 | American Home Products Corporation | Calcium supplement compressed tablets |
| US5374430A (en) | 1986-09-18 | 1994-12-20 | London School Of Pharmacy | Pharmaceutical formulation |
| JP2733849B2 (ja) | 1987-10-12 | 1998-03-30 | ボロディー，ソーマス・ユリウス | 胃腸障害治療のための改良された方法 |
| US5064637A (en) | 1989-05-30 | 1991-11-12 | Board Of Regents, The University Of Texas System | Substituted sulfonamide derivatives which inhibit allergic reactions |
| US5095073A (en) | 1990-03-02 | 1992-03-10 | Exxon Research And Engineering Company | Water soluble rigid rod sulfonated aromatic polyamide |
| SE9003296L (sv) | 1990-10-16 | 1992-04-17 | Kabi Pharmacia Ab | Foerfarande foer att formulera laekemedel |
| US5519014A (en) | 1990-10-22 | 1996-05-21 | Borody; Thomas J. | Treatment of non-inflammatory and non-infectious bowel disorders |
| ES2111659T3 (es) | 1992-03-11 | 1998-03-16 | Asta Medica Ag | Comprimidos, granulados y nodulos con alto contenido en sustancias activas para formas de administracion solidas de alta concentracion. |
| US5498608A (en) | 1994-01-07 | 1996-03-12 | Salix Pharmaceuticals | Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents |
| JPH08169847A (ja) | 1994-12-16 | 1996-07-02 | Morishita Roussel Kk | 固形製剤 |
| US5905073A (en) | 1995-01-06 | 1999-05-18 | Salix Pharmaceuticals, Inc. | Use of 2-hydroxy-5-phenylazobenzoic acid derivatives as colon cancer chemopreventative and chemotherapeutic agents |
| US6562629B1 (en) | 1999-08-11 | 2003-05-13 | Cedars-Sinai Medical Center | Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum |
| US6231888B1 (en) | 1996-01-18 | 2001-05-15 | Perio Products Ltd. | Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps |
| SE9700934D0 (sv) | 1997-03-14 | 1997-03-14 | Astra Ab | New formulation |
| US6551632B2 (en) | 1997-04-01 | 2003-04-22 | Thomas Julius Borody | Methods and compositions for treating inflammatory bowel disease |
| CA2285923C (en) | 1997-04-01 | 2013-03-12 | Thomas Julius Borody | Methods and compositions for treating inflammatory bowel disease |
| AUPO665397A0 (en) | 1997-05-07 | 1997-05-29 | Borody, Thomas Julius | Novel therapy for constipation |
| US6144381A (en) | 1997-05-14 | 2000-11-07 | International Business Machines Corporation | Systems, methods and computer program products for compass navigation of avatars in three dimensional worlds |
| DE19732903A1 (de) | 1997-07-30 | 1999-02-04 | Falk Pharma Gmbh | Pellet-Formulierung zur Behandlung des Intestinaltraktes |
| ATE370961T1 (de) | 1998-05-06 | 2007-09-15 | Genentech Inc | Reinigung von antikörpern durch ionenaustauschchromatographie |
| US5927500A (en) | 1998-06-09 | 1999-07-27 | Milliken & Company | Pharmaceutical containment package |
| AUPP437698A0 (en) | 1998-06-30 | 1998-07-23 | Baumgart, Karl | Methods for treatment of coronary, carotid and other vascular disease |
| TR200100172T2 (tr) | 1998-07-20 | 2001-05-21 | Smithkline Beecham Corporation | Oral katı doz formunda eprosartan içeren biyolojik bakımdan kuvvetlendirilmiş formülasyonlar |
| KR20000011247A (ko) | 1998-07-23 | 2000-02-25 | 김윤 | 다당류를이용한대장선택성약물전달조성물및약학제제 |
| US6326364B1 (en) | 1999-02-08 | 2001-12-04 | Cedars-Sinai Medical Center | Use of 5-aminosalicylates as antimicrobial agents |
| US20030138399A1 (en) | 1999-05-14 | 2003-07-24 | Anton Peter A. | Anti-inflammatory therapy for inflammatory mediated infection |
| ATE311358T1 (de) | 2000-08-29 | 2005-12-15 | Nobex Corp | Immunoregulierende verbindungen, deren derivate und ihre verwendung |
| EP1313699B1 (en) | 2000-08-29 | 2010-03-10 | Biocon Limited | 5-asa derivatives having anti-inflammatory and antibiotic activity and methods of treating diseases therewith |
| US6562871B1 (en) | 2000-11-06 | 2003-05-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | Dry granulation of pharmaceutical formulation comprising mexiletine |
| CA2359812C (en) | 2000-11-20 | 2004-02-10 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple coatings for reduced impact of coating fractures |
| WO2003011117A2 (en) | 2001-07-31 | 2003-02-13 | The General Hospital Corporation | Methods and compositions for treating and preventing distal bowel lesions |
| US6407128B1 (en) | 2001-12-03 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Method for increasing the bioavailability of metaxalone |
| US20030191347A1 (en) | 2002-03-28 | 2003-10-09 | Rolf Keltjens | Venlafaxine base |
| US8216609B2 (en) | 2002-08-05 | 2012-07-10 | Torrent Pharmaceuticals Limited | Modified release composition of highly soluble drugs |
| WO2004082715A1 (ja) | 2003-03-20 | 2004-09-30 | Eisai Co., Ltd. | 炎症性腸疾患治療剤としての併用医薬 |
| US7737133B2 (en) | 2003-09-03 | 2010-06-15 | Agi Therapeutics Ltd. | Formulations and methods of treating inflammatory bowel disease |
| US7825106B2 (en) | 2003-09-03 | 2010-11-02 | Agi Therapeutics Ltd. | Modified release formulations and methods of treating inflammatory bowel disease |
| WO2005030173A1 (en) | 2003-09-25 | 2005-04-07 | Ranbaxy Laboratories Limited | Colon-specific drug delivery using interpolymer complexations |
| JP2007520495A (ja) | 2004-02-06 | 2007-07-26 | ボロディー トーマス ユリウス | 下痢型過敏性腸症候群におけるアミノサリチル酸の使用法 |
| US7452872B2 (en) | 2005-08-24 | 2008-11-18 | Salix Pharmaceuticals, Inc. | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives |
| CA2816276A1 (en) * | 2005-08-24 | 2007-03-01 | Salix Pharmaceuticals, Inc. | Balsalazide formulations and manufacture and use thereof |
| WO2008033125A1 (en) | 2006-09-13 | 2008-03-20 | The Procter & Gamble Company | Methods of treatment for ulcerative colitis using aminosalicylate |
-
2006
- 2006-11-03 US US11/592,854 patent/US8921344B2/en active Active
-
2007
- 2007-03-23 KR KR1020147020483A patent/KR20140098863A/ko not_active Ceased
- 2007-03-23 CA CA3004028A patent/CA3004028C/en active Active
- 2007-03-23 WO PCT/US2007/007438 patent/WO2008063211A2/en not_active Ceased
- 2007-03-23 JP JP2009536219A patent/JP6067203B2/ja not_active Expired - Fee Related
- 2007-03-23 CN CNA2007800491919A patent/CN101610670A/zh active Pending
- 2007-03-23 BR BRPI0717859-0A patent/BRPI0717859A2/pt not_active Application Discontinuation
- 2007-03-23 KR KR1020097011493A patent/KR20090118906A/ko not_active Ceased
- 2007-03-23 EP EP07754015.1A patent/EP2096912B1/en active Active
- 2007-03-23 DK DK07754015.1T patent/DK2096912T3/en active
- 2007-03-23 CA CA2668441A patent/CA2668441C/en active Active
- 2007-03-23 AU AU2007322362A patent/AU2007322362B2/en not_active Ceased
- 2007-03-23 MX MX2009004826A patent/MX2009004826A/es unknown
-
2009
- 2009-05-03 IL IL198513A patent/IL198513B/en active IP Right Grant
-
2012
- 2012-11-12 JP JP2012248573A patent/JP2013032395A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019048843A5 (enExample) | ||
| JP2009514874A5 (enExample) | ||
| JP2014528474A5 (enExample) | ||
| AU2007267135A1 (en) | Long term 24 hour intestinal administration of levodopa/carbidopa | |
| ZA200704744B (en) | Nanoparticulate and controlled release compositions comprising a cephalosporin | |
| JP2012520866A5 (enExample) | ||
| WO2011107855A3 (en) | Sustained release oral liquid suspension dosage form | |
| WO2008122190A1 (en) | The composition comprising l-carnitine or derivatives thereof and its use | |
| JP2010535767A5 (enExample) | ||
| AU2010200722A1 (en) | Methods of treating non-painful bladder disorders using Alpha2Delta subunit calcium channel modulators | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| JP2012533565A5 (enExample) | ||
| WO2008030830A3 (en) | Sustained-release composition and method of use thereof | |
| WO2007012019A3 (en) | Medicaments containing famotidine and ibuprofen and administration of same | |
| CN103919773A (zh) | 9-去甲基小檗碱在制备降血脂药物中的应用 | |
| JP2013544290A5 (enExample) | ||
| Dutta et al. | Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States | |
| CN104955468A (zh) | 一氧化氮浓度增高剂 | |
| JP2018039810A5 (enExample) | ||
| TW200534852A (en) | 4-methylpyrazole formulations for inhibiting ethanol intolerance | |
| CN103919774A (zh) | 去亚甲基小檗碱在制备降血脂药物中的应用 | |
| AU2019237857B2 (en) | Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders | |
| CN114007608A (zh) | 在儿科患者中治疗无义突变介导的杜氏肌营养不良症的方法 | |
| JP2009522294A5 (enExample) | ||
| RU2016144695A (ru) | Комплекс танната ситаглиптина |